talabostat mesylate

DRUG5 trials

Conditions

Advanced Malignant Solid NeoplasmBrain and Central Nervous System TumorsCancer of PancreasCancer of the PancreasCarcinoma, Non-Small Cell LungChildhood Germ Cell TumorKidney CancerLiver Cancer

Early Phase 1

A Pilot Study of BXCL701 in Patients With Pancreatic Cancer

WithdrawnNCT04123574

BioXcel Therapeutics IncCancer of Pancreas, Cancer of the Pancreas, Neoplasms, Pancreatic +2

Start: 2019-10-15End: 2021-12-06Updated: 2022-02-24

Phase 1

Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors

CompletedNCT00303940

National Institutes of Health Clinical Center (CC)Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Kidney Cancer +5

Start: 2005-12-31End: 2010-02-28Target: 26Updated: 2012-03-15

Phase 2

Talabostat in Treating Patients With Metastatic Kidney Cancer

WithdrawnNCT00489710

University of NebraskaKidney Cancer

Start: 2006-12-31End: 2007-05-30Updated: 2023-08-22

Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers

TerminatedNCT04171219

M.D. Anderson Cancer CenterAdvanced Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm

Start: 2020-03-19End: 2025-03-11Updated: 2025-05-16

Phase 3

Study of Talabostat + Docetaxel Versus Docetaxel in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy

TerminatedNCT00243204

Point TherapeuticsCarcinoma, Non-Small Cell Lung

Start: 2006-01-31Target: 400Updated: 2007-06-08

Journal of Clinical Oncology2023-06-011 citations

Targeting innate immunity with BXCL701 in combination with pembrolizumab in patients with advanced solid cancers: Phase 2 basket study.

Journal of Clinical Oncology2021-05-202 citations

382 Targeting innate immunity with BXCL701 in combination with pembrolizumab in patients with advanced solid cancers: phase 2 basket study

Regular and Young Investigator Award Abstracts2020-11-011 citations